first
case
sever
acut
respiratori
syndrom
sar
occur
china
novemb
agent
caus
ill
identifi
novel
coronaviru
sarscoronaviru
sinc
introduct
year
ago
viru
infect
peopl
countri
kill
present
overview
epidemiolog
clinic
present
diagnosi
treatment
sar
base
current
state
knowledg
deriv
publish
studi
person
experi
juli
report
last
known
human
chain
transmiss
sar
broken
newli
discov
coronaviru
sarscov
identifi
caus
sar
sarscovlik
virus
detect
himalayan
palm
civet
raccoondog
market
southern
china
suggest
origin
sarscov
may
wild
anim
given
possibl
human
anim
reservoir
sarscov
may
still
exist
sar
may
season
predilect
concern
sar
may
return
upcom
respiratori
season
guidelin
emphas
need
countri
remain
vigil
maintain
capac
detect
respond
potenti
reemerg
sar
guangdong
provinc
hotel
hong
kong
infect
guest
movement
individu
result
spread
sar
worldwid
spark
major
epicent
outsid
china
figur
rate
spread
epidem
whether
selfsustain
depend
basic
reproduct
number
r
r
defin
averag
number
secondari
case
gener
primari
case
suscept
popul
quantiti
determin
potenti
infecti
agent
start
outbreak
extent
transmiss
absenc
control
measur
abil
control
measur
reduc
spread
cours
epidem
r
effect
reproduct
number
decreas
comparison
r
result
deplet
suscept
person
popul
death
recoveri
subsequ
immun
implement
specif
control
measur
stop
outbreak
r
must
maintain
mathemat
model
earli
phase
singapor
hong
kong
outbreak
institut
control
measur
time
occur
primarili
hospit
set
estim
r
indic
viru
moder
infect
attack
rate
sarscov
rang
exposurehour
depend
clinic
set
unit
measur
signific
limit
calcul
data
base
diagnos
made
clinic
case
definit
reanalysi
requir
result
seropreval
studi
complet
provid
accur
estim
r
sarscov
isol
sputum
sampl
nasal
secret
serum
specimen
fece
sampl
bronchial
wash
evid
suggest
sarscov
transmit
contact
andor
droplet
use
mask
surgic
significantli
decreas
risk
infect
howev
case
defi
explan
base
mode
transmiss
suggest
altern
mode
transmiss
may
also
exist
sarscov
remain
viabl
fece
day
outbreak
amoy
garden
apart
highlight
possibl
fecalor
fecaldroplet
mode
transmiss
number
case
occur
health
care
worker
wear
protect
equip
follow
exposur
highrisk
aerosoland
dropletgener
procedur
airway
manipul
administr
aerosol
medic
noninvas
posit
pressur
ventil
bronchoscopi
intub
intub
necessari
measur
taken
reduc
unnecessari
exposur
health
care
worker
includ
reduc
number
health
care
worker
present
adequ
sedat
paralyz
patient
reduc
cough
updat
infect
control
precaut
patient
sar
avail
center
diseas
control
prevent
cdc
http
wwwcdcgovncidodsarsindexhtm
current
epidemiolog
evid
suggest
transmiss
occur
onset
symptom
symptom
resolut
even
though
shed
sarscov
stool
document
rtpcr
day
resolut
symptom
small
group
patient
appear
highli
infecti
refer
superspread
event
appear
play
import
role
earli
epidem
possibl
explan
enhanc
infect
includ
lack
earli
implement
infectioncontrol
precaut
higher
sarscov
load
larger
amount
respiratori
secret
case
definit
case
definit
sar
base
clinic
epidemiolog
data
develop
outbreak
although
definit
epidemiolog
use
rainer
et
al
shown
low
sensit
diagnosi
patient
earli
diseas
sensit
specif
underscor
import
rapid
accur
diagnost
test
sinc
cdc
develop
updat
sar
surveil
case
definit
base
clinic
epidemiolog
laboratori
criteria
similar
updat
definit
typic
incub
period
sar
rang
day
may
occasion
long
day
frequenc
symptom
onset
diseas
summar
tabl
prodrom
includ
influenzalik
symptom
fever
myalgia
headach
diarrhea
fever
vari
low
high
grade
occasion
absent
present
particularli
older
patient
typic
respiratori
phase
start
day
prodrom
associ
wateri
diarrhea
earli
respiratori
stage
includ
dri
nonproduct
cough
mild
dyspnea
earlyphas
chest
radiograph
often
show
subtl
peripher
pulmonari
infiltr
readili
detect
consolid
groundglass
appear
highresolut
ct
lung
atyp
present
diseas
describ
elsewher
includ
case
involv
fever
respiratori
compon
asymptomat
case
also
describ
small
number
interest
diseas
rare
children
present
appear
milder
spectrum
diseas
onset
diseas
case
may
progress
mild
variant
diseas
character
mild
respiratori
symptom
fever
cough
variant
character
persist
intract
cough
howev
commonli
case
progress
moderatesever
variant
character
seriou
later
respiratori
phase
dyspnea
exert
rest
hypoxia
later
respiratori
phase
typic
occur
day
onset
symptom
tabl
hospit
patient
persist
progress
hypoxia
result
requir
intub
mechan
ventil
among
patient
develop
respiratori
failur
intub
requir
median
day
onset
symptom
subtl
progress
decreas
oxygen
satur
often
indic
imped
respiratori
failur
trigger
moreintens
monitor
prepar
intub
control
circumst
typic
respiratori
phase
last
week
recoveri
phase
begin
day
onset
symptom
clinic
outcom
casefat
rate
recent
outbreak
rang
advanc
age
import
risk
factor
death
patient
age
year
casefat
rate
risk
factor
death
includ
diabet
mellitu
hepat
b
viru
infect
littl
data
exist
regard
longterm
morbid
sar
although
preliminari
studi
suggest
psycholog
impact
diseas
consider
sensit
specif
test
detect
sarscov
yield
result
within
hour
patient
present
urgent
need
mani
test
develop
includ
market
commerci
none
yet
achiev
goal
earli
diagnosi
sar
base
recognit
epidemiolog
linkag
presenc
typic
clinic
laboratori
radiograph
featur
exclus
respiratori
pathogen
none
featur
sar
specif
howev
diagnosi
confirm
sarscovspecif
microbiolog
serolog
studi
although
initi
manag
continu
base
clinic
epidemiolog
assess
likelihood
sarscov
infect
routin
laboratori
test
time
present
routin
hematolog
biochem
test
find
frequent
abnorm
particular
lymphopenia
thrombocytopenia
absenc
neutrophilia
elev
lactic
dehydrogenas
level
elev
creatin
phosphokinas
level
observ
howev
basi
preliminari
analysi
compar
laboratori
featur
caus
communityacquir
pneumonia
none
test
alon
suffici
significantli
alter
pretest
probabl
sar
test
sarscov
serolog
assay
sarscov
includ
immunofluoresc
assay
elisa
western
blot
assay
basi
limit
studi
complet
date
igm
detect
delay
week
onset
symptom
mean
time
igg
seroconvers
estim
day
result
serolog
test
present
use
strategi
rapid
diagnosi
assay
cultur
sarscov
cell
line
rapid
detect
rtpcr
clinic
specimen
avail
sensit
cultur
lower
rtpcr
specif
rtpcr
assay
assur
use
specif
probe
sequenc
rtpcr
product
complet
second
rtpcr
assay
use
primer
amplifi
differ
genom
region
qualitycontrol
measur
place
prevent
falseposit
result
due
laboratori
contamin
analyt
sensit
assay
shown
high
reproduc
detect
limit
copi
viral
rna
howev
basi
result
firstgener
assay
clinic
sensit
sarscov
rtpcr
estim
low
depend
type
specimen
test
time
collect
rel
onset
symptom
sar
specimen
highest
proport
posit
sarscov
use
firstgener
assay
includ
nasopharyng
swab
nasopharyng
aspir
throat
swab
stool
highest
yield
specimen
obtain
day
symptom
onset
associ
highest
yield
specimen
type
correl
time
peak
viru
load
optim
sarscov
rtpcr
assay
regard
target
genom
region
time
specimen
obtain
type
specimen
extract
methodolog
ongo
recent
report
describ
second
gener
assay
clinic
sensit
use
modifi
extract
method
nasopharyng
aspir
obtain
first
day
ill
summari
sampl
test
investig
possibl
sar
appear
tabl
coinfect
sarscov
infecti
agent
exist
result
find
infecti
agent
sarscov
use
rule
sar
present
suffici
evid
recommend
specif
therapi
treatment
sar
sar
easili
distinguish
caus
pneumonia
patient
suspect
sar
pulmonari
infiltr
receiv
appropri
antibiot
coverag
respiratori
failur
primari
caus
acut
morbid
mortal
due
sarscov
infect
occur
case
mechan
ventil
requir
lung
protect
ventil
strategi
use
base
analog
data
treatment
acut
respiratori
distress
syndrom
ard
current
intens
care
unit
experi
manag
sar
fact
barotrauma
appear
one
frequent
complic
sever
sarscov
infect
pneumothorax
andor
pneumomediastinum
occur
ventil
patient
rate
much
higher
rate
observ
larg
studi
ard
antivir
therapi
antivir
agent
use
therapi
sar
includ
ribavirin
ifna
lopinavirritonavir
ribavirin
nucleosid
analogu
vitro
activ
number
rna
dna
virus
includ
anim
coronavirus
ribavirin
wide
use
treatment
sar
initi
report
note
improv
surrog
marker
outcom
resolut
fever
improv
oxygen
radiograph
appear
studi
control
patient
also
receiv
corticosteroid
report
fail
identifi
improv
ribavirin
one
report
identifi
high
frequenc
advers
event
among
patient
treat
highdos
ribavirin
includ
sever
hemolysi
patient
vitro
test
sarscov
indic
ribavirin
activ
viru
clinic
achiev
concentr
postmortem
find
patient
demonstr
high
viru
load
persist
despit
treatment
ribavirin
ifn
cytokin
welldescrib
antivir
activ
ifn
particularli
ifnb
inhibit
sarscov
vitro
openlabel
studi
use
highdos
methylprednisolon
demonstr
morerapid
improv
radiograph
appear
oxygen
recipi
compar
histor
cohort
receiv
lower
dose
corticosteroid
alon
complex
trial
examin
ribavirin
ifn
differ
dose
corticosteroid
also
demonstr
improv
surrog
end
point
radiograph
appear
improv
occur
ifn
recipi
also
receiv
highdos
corticosteroid
lopinavirritonavir
combin
drug
consist
proteas
inhibitor
proven
efficaci
treatment
hiv
lopinavirritonavir
studi
nonrandom
open
label
studi
hong
kong
initi
rescu
therapi
sar
ad
local
standard
therapi
consist
ribavirin
corticosteroid
use
initi
therapi
recipi
signific
reduct
overal
death
rate
intub
rate
compar
match
control
group
receiv
standard
treatment
alon
control
group
howev
lower
rate
steroid
use
lower
mean
dose
make
definit
conclus
difficult
antiinflammatori
immunomodulatori
therapi
includ
corticosteroid
intraven
immunoglobulin
ivig
convalescentphas
serum
plasma
exchang
corticosteroid
wide
use
sar
therapi
preliminari
result
demonstr
decreas
viru
load
increas
antibodi
titer
second
week
ill
time
respiratori
diseas
typic
progress
result
suggest
lung
damag
patient
sarscov
infect
may
immun
mediat
provid
rational
corticosteroid
therapi
patholog
find
consist
cytokin
dysregul
provid
support
theori
lung
damag
immun
mediat
initi
case
report
describ
resolut
fever
improv
oxygen
radiograph
appear
patient
treat
ribavirin
corticosteroid
subsequ
clinician
note
case
mani
patient
progress
despit
receiv
treatment
corticosteroid
higher
dose
puls
steroid
regimen
requir
rescu
therapi
trial
compar
earli
use
puls
versu
nonpuls
corticosteroid
note
differ
requir
ventil
mortal
reveal
improv
oxygen
radiograph
appear
concern
use
prolong
highdos
puls
corticosteroid
regimen
treatment
new
viral
infect
rais
patholog
studi
detect
high
viru
load
patient
die
day
ill
suggest
persist
viral
replic
occur
like
contribut
pathophysiolog
lung
damag
sarscov
infect
use
corticosteroid
could
potenti
increas
prolong
viral
replic
therebi
worsen
diseas
corticosteroid
also
associ
number
wellknown
advers
outcom
includ
immunosuppress
increas
suscept
opportunist
pathogen
particularli
caus
invas
fungal
infect
one
multivari
analysi
patient
sar
use
puls
corticosteroid
therapi
strongli
associ
mortal
although
result
difficult
interpret
sickest
patient
typic
receiv
puls
corticosteroid
salvag
therapi
also
report
china
avascular
necrosisa
wellrecogn
complic
steroid
therapyoccur
patient
recov
sar
ivig
consist
pool
antibodi
multipl
donor
although
ivig
would
expect
contain
antibodi
direct
sarscov
low
rate
background
immun
popul
demonstr
immunomodulatori
properti
may
downregul
cytokin
express
convalescentphas
plasma
sampl
use
treat
sar
hong
kong
china
may
valu
unlik
standard
ivig
prepar
high
level
antisarscov
antibodi
would
present
final
plasma
exchang
use
salvag
therapi
hong
kong
data
exist
assess
efficaci
sar
deadli
new
infecti
diseas
abil
spread
person
person
countri
countri
via
intern
air
travel
despit
subsequ
rapid
spread
viru
worldwid
tradit
public
health
measur
abl
contain
control
outbreak
sarscov
caus
nonspecif
clinic
ill
diagnos
control
diseas
futur
requir
develop
rapid
accur
test
urgent
need
develop
mean
perform
clinic
trial
evalu
treatment
regimen
sar
well
new
diseas
especi
outbreak
situat
